Subscribe

Torrent Pharmaceuticals Limited (TORNTPHARM.NS)

INR4,973.50 +22.40 (+0.45%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address Torrent House 380009
Ahmedabad, IN
CEO Sanjay Gupta
Website torrentpharma.com
IPO 2002-07-01
ISIN INE685A01028

Explore sections of this company profile

Also trades on Bombay Stock Exchange · TORNTPHARM.BO (INR) National Stock Exchange of India · TORNTPHARM.NS (INR)
Description

Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR4,973.50 +22.40 (+0.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
472.9K
Beta
0.15
Float Shares
103.84M
Free Float %
30.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.62% +3.21% +9.22% +2.25% +20.94% +16.81% +41.09% +166.09% +230.90% +564.01% +21,698.35%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
4,973.50
DCF (Unlevered) 7,508.20 +51.0%
DCF (Levered) 9,969.99 +100.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 75% Bullish
Rating 2026-05 Change
Strong Buy 6 0
Buy 15 -1
Hold 6 0
Sell 0 0
Strong Sell 1 0
Quality scores
Altman Z-Score
4.00
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +23.5% ★ Q1'26: +44.3% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +13.2% Q1'26: -21.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +14.3% Q1'26: +20.1% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +24.8% ★ Q1'26: +20.2% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +13.6% ★ Q1'26: +12.3% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    0.0% ★ Q1'26: -0.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.97× Q1'26: 0.99× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.15) × ERP
WACC = 98% × Ke + 2% × Kd (11.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 7,509.04 Current price: 4,973.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2011
actual 		Mar 2012
actual 		Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
11 Rev. Ana.
10 EPS Ana. 		Mar 2027
2 Rev. Ana.
8 EPS Ana. 		Mar 2028
11 Rev. Ana.
10 EPS Ana. 		Mar 2029
6 Rev. Ana.
4 EPS Ana. 		Mar 2030
7 Rev. Ana.
4 EPS Ana.
Revenue
21.15B
est: 22.27B (-5.0%)
25.93B
est: 26.41B (-1.8%)
30.49B
est: 31.51B (-3.2%)
40.32B
est: 39.12B (+3.1%)
45.79B
est: 47.57B (-3.7%)
65.19B
est: 66.92B (-2.6%)
56.72B
est: 59.32B (-4.4%)
58.25B
est: 60.38B (-3.5%)
74.62B
est: 77.54B (-3.8%)
77.80B
est: 79.78B (-2.5%)
78.86B
est: 81.00B (-2.6%)
84.19B
est: 84.74B (-0.7%)
94.64B
est: 95.61B (-1.0%)
105.62B
est: 107.77B (-2.0%)
113.17B
est: 115.61B (-2.1%)
134.48B
127.58B – 137.88B
+16.3% YoY
150.22B
149.31B – 151.13B
+11.7% YoY
168.58B
131.19B – 176.63B
+12.2% YoY
225.91B
199.27B – 232.17B
+34.0% YoY
208.73B
184.11B – 214.51B
-7.6% YoY
EBITDA
4.44B
est: 4.86B (-8.6%)
4.70B
est: 4.95B (-4.9%)
6.90B
est: 5.03B (+37.2%)
9.65B
est: 7.76B (+24.4%)
12.86B
est: 10.47B (+22.8%)
27.64B
est: 17.30B (+59.8%)
15.84B
est: 23.00B (-31.1%)
16.44B
est: 14.32B (+14.8%)
16.77B
est: 16.96B (-1.1%)
22.86B
est: 7.53B (+203.6%)
25.34B
est: 16.57B (+53.0%)
21.41B
est: 18.55B (+15.4%)
28.81B
est: 20.42B (+41.1%)
35.00B
est: 22.35B (+56.6%)
37.19B
est: 33.95B (+9.5%)
39.44B
37.42B – 40.44B
+16.2% YoY
44.06B
43.79B – 44.32B
+11.7% YoY
49.44B
38.47B – 51.80B
+12.2% YoY
66.26B
58.44B – 68.09B
+34.0% YoY
61.22B
53.99B – 62.91B
-7.6% YoY
EBIT
3.81B
est: 4.00B (-4.5%)
3.89B
est: 3.81B (+1.9%)
6.07B
est: 4.49B (+35.4%)
8.78B
est: 6.67B (+31.7%)
10.96B
est: 12.02B (-8.9%)
25.27B
est: 11.51B (+119.5%)
12.91B
est: 20.63B (-37.4%)
12.36B
est: 10.84B (+14.0%)
10.63B
est: 11.98B (-11.3%)
16.35B
est: 10.36B (+57.8%)
18.77B
est: 16.04B (+17.0%)
14.79B
est: 17.97B (-17.7%)
21.79B
est: 19.78B (+10.2%)
27.05B
est: 21.65B (+24.9%)
29.24B
est: 27.04B (+8.1%)
31.42B
29.80B – 32.21B
+16.2% YoY
35.09B
34.88B – 35.31B
+11.7% YoY
39.38B
30.65B – 41.26B
+12.2% YoY
52.78B
46.55B – 54.24B
+34.0% YoY
48.76B
43.01B – 50.11B
-7.6% YoY
Net Income
2.70B
est: 2.69B (+0.5%)
2.84B
est: 3.16B (-10.1%)
4.33B
est: 3.39B (+27.7%)
6.64B
est: 5.00B (+32.7%)
7.51B
est: 8.38B (-10.4%)
17.33B
est: 10.42B (+66.3%)
9.34B
est: 15.54B (-39.9%)
6.78B
est: 9.45B (-28.3%)
4.36B
est: 8.64B (-49.5%)
10.25B
est: 4.48B (+128.6%)
12.52B
est: 10.85B (+15.4%)
7.77B
est: 12.14B (-36.0%)
12.45B
est: 13.37B (-6.8%)
16.56B
est: 14.63B (+13.2%)
19.11B
est: 19.45B (-1.7%)
23.89B
21.81B – 26.82B
+22.9% YoY
27.48B
23.48B – 33.01B
+15.0% YoY
34.61B
25.14B – 41.68B
+25.9% YoY
41.25B
34.92B – 42.73B
+19.2% YoY
—
— – —
-100.0% YoY
SGA
5.92B
est: 8.52B (-30.5%)
5.70B
est: 10.38B (-45.1%)
13.15B
est: 10.99B (+19.7%)
8.77B
est: 12.52B (-29.9%)
8.77B
est: 22.01B (-60.1%)
8.42B
est: 28.04B (-70.0%)
9.93B
est: 16.86B (-41.1%)
11.35B
est: 22.17B (-48.8%)
14.04B
est: 30.85B (-54.5%)
14.42B
est: 29.78B (-51.6%)
14.60B
est: 30.79B (-52.6%)
15.48B
est: 34.47B (-55.1%)
17.05B
est: 37.95B (-55.1%)
20.17B
est: 41.54B (-51.4%)
22.71B
est: 21.99B (+3.3%)
25.54B
24.23B – 26.19B
+16.2% YoY
28.53B
28.36B – 28.70B
+11.7% YoY
32.02B
24.92B – 33.55B
+12.2% YoY
42.91B
37.85B – 44.10B
+34.0% YoY
39.64B
34.97B – 40.74B
-7.6% YoY
EPS
7.98
est: 17.99 (-55.6%)
8.39
est: 20.88 (-59.8%)
12.79
est: 24.51 (-47.8%)
19.61
est: 34.29 (-42.8%)
22.19
est: 22.29 (-0.5%)
51.21
est: 50.75 (+0.9%)
27.59
est: 28.45 (-3.0%)
20.04
est: 20.96 (-4.4%)
12.89
est: 23.78 (-45.8%)
30.28
est: 28.25 (+7.2%)
36.99
est: 36.67 (+0.9%)
22.96
est: 35.28 (-34.9%)
36.79
est: 37.67 (-2.3%)
48.94
est: 47.37 (+3.3%)
56.47
est: 57.33 (-1.5%)
70.60
64.45 – 79.27
+23.1% YoY
81.22
69.38 – 97.56
+15.0% YoY
102.28
74.29 – 123.16
+25.9% YoY
121.90
103.21 – 126.29
+19.2% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-15 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
12.33B
OE per share TTM
36.40
Owner's Yield
0.81%
Maintenance CapEx ratio
6.22%
Maint CapEx / Avg PPE
38.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
2.20M
Shares Outstanding
338.45M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ashish Hajarnish Executive Director of Operations 77M male
Aman Mehta MD & Whole-Time Director 76M male
Sudhir Menon Executive Director of Finance & Chief Financial Officer 16M male
Jaydip Bhatt Vice President of Human Resource — male
Sanjay Gupta President and Chief Executive Officer of Torrent Pharma USA — male
Geena V. Malhotra Chief Technology Officer — female
Chintan Trivedi Company Secretary & Compliance Officer — male
Abdullah Salam Said Al Abri Chief Customer Service Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic